Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis

por Seret, Guillaume, Hanrotel, Catherine, Bendaoud, Boutahar, Le Meur, Yannick, Renaudineau, Yves
Publicado 2013

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

por Bordron, Anne, Bagacean, Cristina, Mohr, Audrey, Tempescul, Adrian, Bendaoud, Boutahar, Deshayes, Stéphanie, Dalbies, Florence, Buors, Caroline, Saad, Hussam, Berthou, Christian, Pers, Jacques-Olivier, Renaudineau, Yves
Publicado 2018

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

por Bagacean, Cristina, Tempescul, Adrian, Ternant, David, Banet, Anne, Douet-Guilbert, Nathalie, Bordron, Anne, Bendaoud, Boutahar, Saad, Hussam, Zdrenghea, Mihnea, Berthou, Christian, Paintaud, Gilles, Renaudineau, Yves
Publicado 2019